The price-to-earnings ratio for Halozyme Therapeutics Inc. (NASDAQ: HALO) is above average at 18.24x. The 36-month beta value for HALO is also noteworthy at 1.26. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for HALO is 125.74M, and at present, short sellers hold a 6.55% of that float. The average trading volume of HALO on April 26, 2024 was 1.04M shares.
HALO) stock’s latest price update
Halozyme Therapeutics Inc. (NASDAQ: HALO)’s stock price has decreased by -1.69 compared to its previous closing price of 39.12. However, the company has seen a 1.72% increase in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-24 that The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here’s why you should take advantage.
HALO’s Market Performance
HALO’s stock has risen by 1.72% in the past week, with a monthly drop of -4.04% and a quarterly rise of 11.45%. The volatility ratio for the week is 2.01% while the volatility levels for the last 30 days are 2.32% for Halozyme Therapeutics Inc. The simple moving average for the past 20 days is -2.61% for HALO’s stock, with a -0.94% simple moving average for the past 200 days.
Analysts’ Opinion of HALO
Many brokerage firms have already submitted their reports for HALO stocks, with TD Cowen repeating the rating for HALO by listing it as a “Outperform.” The predicted price for HALO in the upcoming period, according to TD Cowen is $54 based on the research report published on February 29, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see HALO reach a price target of $61. The rating they have provided for HALO stocks is “Buy” according to the report published on July 24th, 2023.
Goldman gave a rating of “Neutral” to HALO, setting the target price at $45 in the report published on July 24th of the previous year.
HALO Trading at -2.99% from the 50-Day Moving Average
After a stumble in the market that brought HALO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.53% of loss for the given period.
Volatility was left at 2.32%, however, over the last 30 days, the volatility rate increased by 2.01%, as shares sank -5.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.03% upper at present.
During the last 5 trading sessions, HALO rose by +1.72%, which changed the moving average for the period of 200-days by +3.67% in comparison to the 20-day moving average, which settled at $39.38. In addition, Halozyme Therapeutics Inc. saw 4.06% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HALO starting from LaBarre Michael J., who sale 10,000 shares at the price of $38.49 back on Apr 17 ’24. After this action, LaBarre Michael J. now owns 168,176 shares of Halozyme Therapeutics Inc., valued at $384,890 using the latest closing price.
LaBarre Michael J., the SVP, CHIEF TECHNICAL OFFICER of Halozyme Therapeutics Inc., sale 10,000 shares at $38.35 during a trade that took place back on Apr 16 ’24, which means that LaBarre Michael J. is holding 168,176 shares at $383,500 based on the most recent closing price.
Stock Fundamentals for HALO
Current profitability levels for the company are sitting at:
- 0.41 for the present operating margin
- 0.77 for the gross margin
The net margin for Halozyme Therapeutics Inc. stands at 0.34. The total capital return value is set at 0.21. Equity return is now at value 222.07, with 15.75 for asset returns.
Based on Halozyme Therapeutics Inc. (HALO), the company’s capital structure generated 0.95 points at debt to capital in total, while cash flow to debt ratio is standing at 0.25. The debt to equity ratio resting at 18.27. The interest coverage ratio of the stock is 17.99.
Currently, EBITDA for the company is 422.43 million with net debt to EBITDA at 3.31. When we switch over and look at the enterprise to sales, we see a ratio of 7.56. The receivables turnover for the company is 3.54for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.64.
Conclusion
In summary, Halozyme Therapeutics Inc. (HALO) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
